

Redeye Initiates Coverage of Qlife

Redeye initiates coverage of Qlife, which aims to bring clinical grade biomarker testing to the home setting thanks to its Ego system. Qlife has already achieved sales of SEK77m of devices and tests for SARS-CoV-2, but it will now concentrate on CRP biomarker tests. We believe the technology may prove to be disruptive in the market.

[Read more and download the Research Report.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

[Redeye Initiates Coverage of Qlife](#)